ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OVB Ovoca Bio Plc

0.70
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ovoca Bio Plc LSE:OVB London Ordinary Share IE00B4XVDC01 EUR0.125 (CDI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.70 0.60 0.80 0.70 0.70 0.70 26,313 08:00:01
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 1.46M -5.61M -0.0688 -0.10 570.95k

Ovoca Bio PLC Result of EGM (2826P)

16/02/2021 2:00pm

UK Regulatory


Ovoca Bio (LSE:OVB)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Ovoca Bio Charts.

TIDMOVB

RNS Number : 2826P

Ovoca Bio PLC

16 February 2021

Ovoca Bio plc

("Ovoca" or the "Company")

Result of Extraordinary General Meeting

Dublin, Ireland, 16 February 2021 - Ovoca Bio plc (LSE: OVB; ISE: OVXA), a biopharmaceutical company with a focus on women's health, announces that each of the resolutions proposed at the Extraordinary General Meeting of the Company, held earlier today, were passed.

The full text of each resolution was included in the Notice of Extraordinary General Meeting of the Company, circulated to shareholders on 25 January 2021. The resolutions relate to the replacement of CREST with Euroclear Bank for electronic settlement of trading in the ordinary shares of the Company.

Voting on the resolutions was conducted by poll, and the details of the poll vote are set out below:

 
                                                                              % of ISC 
                          Votes for      %  Votes Against     %  Votes Total     Voted  Votes Withheld 
Resolution 1: 
 Shareholders Consent 
 to Migration            35,370,233  99.99          1,880  0.01   35,372,113     39.99               0 
                         ----------  -----  -------------  ----  -----------  --------  -------------- 
Resolution 2: 
 Approval and Adoption 
 of New Articles 
 of Association 
 of the Company          35,370,233  99.99          1,880  0.01   35,372,113     39.99               0 
                         ----------  -----  -------------  ----  -----------  --------  -------------- 
Resolution 3: 
 to give effect 
 to aspects of 
 the Migration           35,370,233  99.99          1,880  0.01   35,372,113     39.99               0 
                         ----------  -----  -------------  ----  -----------  --------  -------------- 
 

Notes

1. Any proxy appointments which gave discretion to the Chair have been included in the "votes for" total.

2. A "Vote Withheld" is not a valid vote in Irish law and was not counted in the calculation of the proportion of the votes "For" or "Against" a resolution.

End

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel +353 1 661 9819

info@ovocabio.com

Davy (Nominated Adviser, Euronext Growth Advisor and Broker)

John Frain / Daragh O'Reilly

Tel: +353 1 679 6363

Consilium Strategic Communications

Chris Gardner, Chris Welsh, Carina Jurs

ovocabio@consilium-comms.com

Tel: +44 (0)20 3709 5700

About Ovoca Bio

Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD).

The Company's lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD.

Ovoca Bio is seeking to develop the drug for major global markets - in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMDZGMZFVDGMZM

(END) Dow Jones Newswires

February 16, 2021 09:00 ET (14:00 GMT)

1 Year Ovoca Bio Chart

1 Year Ovoca Bio Chart

1 Month Ovoca Bio Chart

1 Month Ovoca Bio Chart

Your Recent History

Delayed Upgrade Clock